Loading clinical trials...
Loading clinical trials...
A PHASE IIIB, OPEN, MULTI-CENTER STUDY TO EVALUATE THE LONG-TERM ANTIBODY PERSISTENCE AT 6, 7, 8, 9 AND 10 YEARS AFTER THE ADMINISTRATION OF ONE DOSE OF THE MENINGOCOCCAL CONJUGATE VACCINE MENACWY-TT VERSUS ONE DOSE OF MENINGITEC(REGISTERED) VACCINE OR ONE DOSE OF THE MENINGOCOCCAL POLYSACCHARIDE VACCINE MENCEVAX(REGISTERED) ACWY, AND TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A BOOSTER DOSE OF MENACWY-TT VACCINE ADMINISTERED 10 YEARS AFTER PRIMARY VACCINATION OF 1-10 YEAR OLD SUBJECTS WITH MENACWY-TT, MENINGITEC(REGISTERED) OR MENCEVAX(REGISTERED) ACWY.
Conditions
Interventions
Meningococcal vaccine GSK134612
Locations
9
Finland
Espoo Vaccine Research Clinic
Espoo, Finland
South Helsinki Vaccine Research Clinic
Helsinki, Finland
Helsinki East Vaccine Research Clinic
Helsinki, Finland
Jarvenpaa Vaccine Research Clinic
Jarvenpaa, Finland
Tampereen yliopisto/ Oulun rokotetutkimusklinikka
Oulu, Finland
Tampereen yliopisto/ Porin rokotetutkimusklinikka
Pori, Finland
Start Date
October 1, 2013
Primary Completion Date
December 1, 2017
Completion Date
June 1, 2018
Last Updated
June 7, 2019
NCT04886154
NCT00508261
NCT01755689
NCT00974363
NCT00126984
NCT00196963
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions